Literature DB >> 17610597

Visceral leishmaniasis: a threat to immunocompromised patients in non-endemic areas?

M Weisser1, B Khanlari, L Terracciano, C Arber, A Gratwohl, S Bassetti, C Hatz, M Battegay, U Flückiger.   

Abstract

Visceral leishmaniasis is rare in western Europe, but may be life-threatening in immunocompromised patients. It is therefore important to understand the incidence of the disease in a non-endemic area and its relationship with immunosuppressive conditions. Between 1990 and 2005, 12 patients were diagnosed with leishmaniasis at Basel University Hospital, Switzerland. Eleven presented with visceral symptoms and ten had an underlying immunosuppressive condition. Since increasing numbers of immunosuppressed patients have a history of travel to endemic countries, an association of visceral leishmaniasis with cellular immunosuppression (other than that associated with human immunodeficiency virus) might become more frequent in non-endemic areas.

Entities:  

Mesh:

Year:  2007        PMID: 17610597     DOI: 10.1111/j.1469-0691.2007.01755.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  9 in total

1.  Asymptomatic Visceral Leishmania infantum Infection in US Soldiers Deployed to Iraq.

Authors:  Rupal M Mody; Ines Lakhal-Naouar; Jeffrey E Sherwood; Nancy L Koles; Dutchabong Shaw; Daniel P Bigley; Edgie-Mark A Co; Nathanial K Copeland; Linda L Jagodzinski; Rami M Mukbel; Rebecca A Smiley; Robert C Duncan; Shaden Kamhawi; Selma M B Jeronimo; Robert F DeFraites; Naomi E Aronson
Journal:  Clin Infect Dis       Date:  2019-05-30       Impact factor: 9.079

2.  New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas.

Authors:  Kathryn M Dupnik; Eliana L Nascimento; Joao F Rodrigues-Neto; Tatjana Keesen; Maria Zélia Fernandes; Iraci Duarte; Selma M B Jeronimo
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

3.  Visceral leishmaniasis in immunosuppressed Caucasian patient.

Authors:  Muhammad Toqeer; Nadeem Rahman; Mark W Whitehead; Diana Lockwood
Journal:  BMJ Case Rep       Date:  2012-05-08

Review 4.  Leishmaniasis: new insights from an old and neglected disease.

Authors:  S Antinori; L Schifanella; M Corbellino
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-01       Impact factor: 3.267

5.  [Kala azar - Lethal course of visceral leishmaniasis. Synchronous infection with Leishmania donovani/infantum complex and Leishmania major in a patient after Mediterranean vacation].

Authors:  C Posch; J Walochnik; A Gschnait; H Feichtinger; K Rappersberger
Journal:  Hautarzt       Date:  2012-12       Impact factor: 0.751

6.  Visceral leishmaniasis and immunocompromise as a risk factor for the development of visceral leishmaniasis: a changing pattern at the hospital for tropical diseases, london.

Authors:  Kate Fletcher; Rita Issa; D N J Lockwood
Journal:  PLoS One       Date:  2015-04-01       Impact factor: 3.240

7.  The double burden of diabetes and global infection in low and middle-income countries.

Authors:  Susanna Dunachie; Parinya Chamnan
Journal:  Trans R Soc Trop Med Hyg       Date:  2019-02-01       Impact factor: 2.184

Review 8.  Non-Endemic Leishmaniases Reported Globally in Humans between 2000 and 2021-A Comprehensive Review.

Authors:  Rafael Rocha; André Pereira; Carla Maia
Journal:  Pathogens       Date:  2022-08-16

9.  Prolonged fever, hepatosplenomegaly, and pancytopenia in a 46-year-old woman.

Authors:  Liran Levy; Abedelmajeed Nasereddin; Moshe Rav-Acha; Meirav Kedmi; Deborah Rund; Moshe E Gatt
Journal:  PLoS Med       Date:  2009-04-14       Impact factor: 11.069

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.